Overview

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient With Pancreatic Cancer

Status:
Unknown status

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeyondBio Inc.

Treatments:

Gemcitabine